

Andre Larente from DIAGNOS to Host InvestorTalk (04.24.2024)

written by InvestorNews | April 24, 2024

InvestorNews is hosting an InvestorTalk this morning with [André Larente](#), CEO, President, and Director from [DIAGNOS Inc.](#) (TSXV: ADK | OTCQB: DGN0F) at 9 AM EST. To participate in the InvestorTalk, please [click here](#)

DIAGNOS has [76,648,586](#) shares outstanding and a market cap of [CAD\\$22,994,576](#).

In preparing for this morning's InvestorTalk here are the latest news releases for your review:

- April 16, 2024 – DIAGNOS to expedite application for Medical Device License to Health Canada and US FDA related to its 4 new analysis modules, and is planning ISO 27001 certification – [click here](#)
- April 9, 2024 – DIAGNOS Inc. to Present at the Technology Hybrid Investor Conference April 11th – [click here](#)
- April 2, 2024 – DIAGNOS Welcomes Dr. Philippe Couillard to its Board of Directors – [click here](#)

5-Data Points from the most recent news release:

1. **Approval Process:** Diagnos Inc. is working to obtain Health Canada and U.S. FDA approvals for four additional AI analysis modules, with plans to commercialize these during Q3 2024.
2. **Module Functions:** The new AI modules are designed to assist healthcare professionals in identifying abnormal Optical Coherence Tomography (OCT) retinal images and in

grading Fundus images for signs of AMD (Age-Related Macular Degeneration), DR (Diabetic Retinopathy), and HR (Hypertensive Retinopathy).

3. **Impact on Revenue and Distribution:** The modernization of Diagnos' Health Canada license is seen as essential for distribution partnerships, including with Essilor Luxottica for the Canadian market, and for potential expansion into the U.S. market. This expansion is expected to accelerate revenue growth for Diagnos.
4. **ISO 27001 Certification:** Diagnos is also progressing towards obtaining ISO 27001 Cyber Security certification, which is a requirement from current and prospective customers to enhance data security.
5. **Company Background and AI Platform:** Diagnos is a publicly traded company on the TSX Venture Exchange and the OTCQB. It specializes in early detection of critical health issues using its FLAIRE AI platform, which supports the development and application of AI technologies such as CARA (Computer Assisted Retina Analysis) for enhanced retinal image analysis.

(04.24.2024 – Premarket, [Source](#))



The last InvestorNews Interview was on December 14, 2023, and

was titled: [Andre Larente from DIAGNOS on Deal with World's Largest Eyecare Retailer EssilorLuxottica](#)

Andre Larente from DIAGNOS on Deal with World's Largest Eyecare Retailer EssilorLuxottica

written by InvestorNews | April 24, 2024

InvestorNews host Tracy Weslosky recently conducted an insightful interview with André Larente, President and Director of [DIAGNOS Inc.](#) (TSXV: ADK | OTCQB: DGN0F), to discuss the company's exclusive [distribution agreement](#) with EssilorLuxottica. DIAGNOS, known for its pioneering FLAIRE platform based on Artificial Intelligence (AI), has solidified its position as a leading provider of retinal analysis technology through this partnership. This agreement, announced on December 11th, is a significant milestone for DIAGNOS, signaling its growing influence in the AI and healthcare technical services sector.

During the interview, Larente highlighted the capabilities of DIAGNOS' AI-powered retinal image analysis technology, which has been acclaimed for its role in the early detection of various eye conditions. This breakthrough technology not only enhances the quality of eye health care but also significantly impacts patient lives positively. The partnership with EssilorLuxottica, a global leader in vision care with an \$87Bn market cap, is set

for an initial three-year term with potential for renewal.

Under the agreement, DIAGNOS will be compensated on a per patient exam basis across EssilorLuxottica's client network. Larente expressed his pride in the partnership, emphasizing the pivotal role it plays in DIAGNOS' mission to broaden the accessibility of its retinal analysis technology. This collaboration is expected to contribute significantly to visual health in Canada and potentially the USA. Both DIAGNOS and EssilorLuxottica are committed to advancing eye health and technology, with a focus on offering innovative solutions to optometrists that will transform the early detection and quality of eye care in the region.

In summary, DIAGNOS' exclusive distribution agreement with EssilorLuxottica marks a key development in its journey, reinforcing its commitment to revolutionizing eye health care through advanced AI-based technologies. This collaboration is set to make a profound impact on the early detection and treatment of eye conditions, benefiting a wide range of patients and healthcare providers.

To access the complete interview, [click here](#)

Don't miss other InvestorNews interviews. Subscribe to the InvestorNews YouTube channel by [clicking here](#)

About DIAGNOS Inc.

DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.

To learn more about DIAGNOS Inc., [click here](#)

Disclaimer: DIAGNOS Inc. is an advertorial member of InvestorNews Inc.

This interview, which was produced by InvestorNews Inc. ("InvestorNews"), does not contain, nor does it purport to contain, a summary of all material information concerning the Company, including important disclosure and risk factors associated with the Company, its business and an investment in its securities. InvestorNews offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This interview and any transcriptions or reproductions thereof (collectively, this "presentation") does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to subscribe for or purchase any securities in the Company. The information in this presentation is provided for informational purposes only and may be subject to updating, completion or revision, and except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any information herein. This presentation may contain "forward-looking statements" within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company's business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company's financial condition or results of operations may negatively impact the value of its securities. This presentation should not be considered as the giving of investment advice by the Company or any of its directors, officers, agents, employees or advisors. Each person to whom this presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. Prospective investors are urged to review the Company's profile on [SedarPlus.ca](https://www.sedarplus.ca) and to carry out independent investigations in order to determine their interest in investing in the Company.

André Larente provides an update on the 'exponential growth' of the Diagnos AI-based telemedicine platform

written by InvestorNews | April 24, 2024

In a recent InvestorIntel interview, Tracy Weslosky spoke with André Larente, President of [Diagnos Inc.](https://www.diagnosinc.com) (TSXV: ADK | OTCQB: DGNOF) about Diagnos' recent milestones including several multi-year contracts for their AI-based telemedicine platform as they continue to show a pattern of 'exponential growth.'

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), André Larente went on to say that Diagnos recently announced a [three-year contract](#) renewal to provide its telemedicine platform to Optina Diagnostics to create tests for early detection of Alzheimer's Disease. Diagnos has also signed [an MoU](#) with Essilor International, the world's leading ophthalmic optics company. He also provided an update on Diagnos' 7-year agreement with New Look Vision Group Inc. and explained how the deal will change New Look "from being an eyewear provider to becoming an eyecare provider."

To watch the full interview, [click here](#).

About DIAGNOS:

DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).

To learn more about Diagnos Inc., [click here](#)

Disclaimer: Diagnos Inc. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp. (IIC) does not contain, nor does it purport to contain, a summary of all the material information concerning the "Company" being interviewed. IIC offers no representations or warranties

that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on [Sedar.com](https://www.sedar.com) and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please email info@investorintel.com.

Diagnos' André Larente on Entering the DACH and Central European Healthcare Market

written by InvestorNews | April 24, 2024

In a recent InvestorIntel interview, Tracy Weslosky spoke with André Larente President of [Diagnos Inc.](#) (TSXV: ADK | OTCQB: DGNOF) about Diagnos' [distribution agreement](#) to enter the healthcare market in both DACH and Central European countries.

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), Mr. Larente went on to say that the region is a very large market as a large majority of patients suffer from diabetes and hypertension. He also provided an update on a successful [Proof-of-Concept pilot study](#) of its stroke predictor (CARA-ST) based on images of the retina. He said that with a 99% success rate, the pilot study was very successful in identifying people at an early stage of being at risk of having a stroke.

To watch the full interview, [click here](#).

About Diagnos Inc.

DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA's AI-based image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health

Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).

To learn more about Diagnos Inc., [click here](#)

Disclaimer: Diagnos Inc. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp. (IIC) does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on www.sedar.com and to carry out independent investigations in order to determine their interest in investing

in the Company.

If you have any questions surrounding the content of this interview, please email info@investorintel.com.

Diagnos' Andre Larente on the benefits of using AI for the early detection of critical health issues

written by InvestorNews | April 24, 2024

"Our (AI) technology works, its in production (CARA). We are fully funded...the markets we are going after are extremely big..." are excerpts that Andre Larente of [Diagnos Inc.](#) (TSXV: ADK | OTCQB: DGN0F) offered Tracy Weslosky of InvestorIntel in a recent interview.

Tracy starts the interview by identifying the increasing interest from the global market on the Canadian biotech sector. She asks Andre to identify their competitive advantages for investors seeking to understand this market better. Andre explains "we specialize in using AI to tackle some of the medical imaging issues in the world."

Click [here](#) to hear the full interview and learn more about how Diagnos offers early detection medical tests for a wide spectrum of critical medical issues that range from diabetes to cardiovascular issues.

About [Diagnos](#):

Diagnos Inc. (TSXV: ADK | OTCQB: DGNOF) is a publicly traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time. CARA complies with local regulations, is FDA cleared for commercialization in the United States of America is Health Canada licensed for commercialization in Canada and is CE marking compliant in Europe.

Disclaimer: Diagnos Inc. is an advertorial member of InvestorIntel Corp.